zanubrutinib
-
Top 10 best-selling oncology drugs
The bright past is worth learning from by R&D personnel of later generations and their role and responsibility is to realize the commercialization of today’s cutting-edge technologies
-
荷包满满的赛诺菲能否靠另辟蹊径在BTK抑制剂竞赛中杀出重围?
在出售了再生元2160万股股票后,赛诺菲可谓“粮草”充实,这为接下来适宜的收购、合作提供良好的经济基础。资金雄厚的赛诺菲于近日签下了他自出售再生元股票后“买买买”的第…